Valneva (VALN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Valneva has submitted an application to the U.S. FDA to extend the use of its chikungunya vaccine, IXCHIQ®, to adolescents and highlight its long-term antibody persistence. The vaccine, already approved for adults, showed a 99.1% immune response in adolescents with sustained protection over two years. Valneva aims to increase accessibility and expand market opportunities with potential approvals in new regions.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Paramount (PARA) Turned Down Apollo Global Management Seven Times
- Ford (NYSE:F) Calls for EV Incentives in the United Kingdom
- Intel’s (NASDAQ:INTC) $8B Payout Catches Workers’ Attention
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
